Sun Pharma presents Phase 3 data for WINLEVI clascoterone cream 1Percentage

31 Mar 2022 , 01:33 AM

Sun Pharmaceuticals Industries announced that the Companys wholly owned US subsidiary presented data from two pivotal Phase 3 clinical trials of WINLEVI clascoterone cream 1Percentage for the topical treatment of acne vulgaris acne The results which showed favorable safety and efficacy data in patients 12 years of age and older with acne were reported today in a poster podium presentation at the American Academy of Dermatology AAD 2022 Annual Meeting in Boston Massachusetts